{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T03:00:18Z","timestamp":1790391618189,"version":"4.1.0"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004332","name":"Seoul National University Hospital","doi-asserted-by":"publisher","award":["18-2023-0010"],"award-info":[{"award-number":["18-2023-0010"]}],"id":[{"id":"10.13039\/501100004332","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Immunological Methods"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.jim.2026.114124","type":"journal-article","created":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T00:07:54Z","timestamp":1790035674000},"page":"114124","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Development and validation of an ELISA-based assay for detecting anti-idursulfase beta IgE antibodies in human serum using a conjugated IgG-IgE positive control antibody"],"prefix":"10.1016","volume":"551","author":[{"given":"Ha Wook","family":"Chung","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shi Nae","family":"Kwon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeungwoon","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeong Hun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jim.2026.114124_bb0005","series-title":"Cellular and Molecular Immunology","author":"Abbas","year":"2021"},{"issue":"20","key":"10.1016\/j.jim.2026.114124_bb0010","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.4155\/bio-2019-0185","article-title":"Assessing the long-term stability of anti-drug antibodies in method validation: what is the added value?","volume":"11","author":"Boridy","year":"2019","journal-title":"Bioanalysis"},{"key":"10.1016\/j.jim.2026.114124_bb0015","article-title":"Long-term experience with idursulfase beta (Hunterase) in two adolescent patients with MPS II: a case series","volume":"36","author":"Chan","year":"2023","journal-title":"Mol. Genet. Metab. Rep."},{"key":"10.1016\/j.jim.2026.114124_bb0020","doi-asserted-by":"crossref","DOI":"10.1208\/s12248-019-0386-y","article-title":"Recommendations for the development and validation of immunogenicity assays in support of biosimilar programs","volume":"22","author":"Civoli","year":"2020","journal-title":"AAPS J."},{"key":"10.1016\/j.jim.2026.114124_bb0025","doi-asserted-by":"crossref","DOI":"10.1017\/S1462399408000550","article-title":"The mucopolysaccharidoses: a success of molecular medicine","volume":"10","author":"Clarke","year":"2008","journal-title":"Expert Rev. Mol. Med."},{"key":"10.1016\/j.jim.2026.114124_bb0030","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1186\/s13052-018-0562-1","article-title":"Enzyme replacement therapy: efficacy and limitations","volume":"44","author":"Concolino","year":"2018","journal-title":"Ital. J. Pediatr."},{"issue":"4","key":"10.1016\/j.jim.2026.114124_bb0035","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21041258","article-title":"Mucopolysaccharidosis type II: one hundred years of research, diagnosis, and treatment","volume":"21","author":"D\u2019Avanzo","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jim.2026.114124_bb0040","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1208\/s12248-017-0107-3","article-title":"Recommendations for systematic statistical computation of immunogenicity cut points","volume":"19","author":"Devanarayan","year":"2017","journal-title":"AAPS J."},{"key":"10.1016\/j.jim.2026.114124_bb0045","author":"European Medicines Agency"},{"issue":"17","key":"10.1016\/j.jim.2026.114124_bb0050","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22179181","article-title":"Enzyme therapy: current challenges and future perspectives","volume":"22","author":"de la Fuente","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jim.2026.114124_bb0055","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1590\/S1415-47572010005000093","article-title":"Mucopolysaccharidosis I, II, and VI: brief review and guidelines for treatment","volume":"33","author":"Giugliani","year":"2010","journal-title":"Genet. Mol. Biol."},{"key":"10.1016\/j.jim.2026.114124_bb0060","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1208\/s12248-020-00530-4","article-title":"Current considerations for immunoglobulin isotype characterization of antibody response against biotherapeutics","volume":"22","author":"Gorovits","year":"2020","journal-title":"AAPS J."},{"issue":"8","key":"10.1016\/j.jim.2026.114124_bb0065","doi-asserted-by":"crossref","first-page":"710","DOI":"10.2174\/0929866524666170724113452","article-title":"The enzymatic degradation of heparan Sulfate","volume":"24","author":"Griffin","year":"2017","journal-title":"Protein Pept. Lett."},{"key":"10.1016\/j.jim.2026.114124_bb0070","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1111\/cei.12742","article-title":"From the bench to clinical practice: understanding the challenges and uncertainties in immunogenicity testing for biopharmaceuticals","volume":"184","author":"Gunn","year":"2016","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.jim.2026.114124_bb0075","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1208\/s12248-020-00439-y","article-title":"Correction to: development and utility of an ELISA method for sensitive and specific detection of IgE antidrug antibodies","volume":"22","author":"Jiang","year":"2020","journal-title":"AAPS J."},{"key":"10.1016\/j.jim.2026.114124_bb0080","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1038\/jhg.2016.133","article-title":"Comparative study of idursulfase beta and idursulfase in vitro and in vivo","volume":"62","author":"Kim","year":"2017","journal-title":"J. Hum. Genet."},{"key":"10.1016\/j.jim.2026.114124_bb0085","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1111\/all.12155","article-title":"IgE-mediated anaphylaxis and allergic reactions to idursulfase in patients with hunter syndrome","volume":"68","author":"Kim","year":"2013","journal-title":"Allergy"},{"key":"10.1016\/j.jim.2026.114124_bb0090","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1093\/ilar.46.3.269","article-title":"Critical steps in the production of polyclonal and monoclonal antibodies: evaluation and recommendations","volume":"46","author":"Leenaars","year":"2005","journal-title":"ILAR J."},{"key":"10.1016\/j.jim.2026.114124_bb0095","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jim.2004.06.002","article-title":"Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products","volume":"289","author":"Mire-Sluis","year":"2004","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.jim.2026.114124_bb0100","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1208\/s12248-021-00649-y","article-title":"Anti-drug antibody validation testing and reporting harmonization","volume":"24","author":"Myler","year":"2022","journal-title":"AAPS J."},{"key":"10.1016\/j.jim.2026.114124_bb0105","first-page":"28","article-title":"Case report of treatment experience with idursulfase beta (Hunterase) in an adolescent patient with MPS II","volume":"12","author":"Ngu","year":"2017","journal-title":"Mol. Genet. Metab. Rep."},{"key":"10.1016\/j.jim.2026.114124_bb0110","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1016\/j.pedneo.2022.10.001","article-title":"Current and new therapies for mucopolysaccharidoses","volume":"64","author":"Penon-Portmann","year":"2023","journal-title":"Pediatr. Neonatol."},{"issue":"10","key":"10.1016\/j.jim.2026.114124_bb0115","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.4155\/bio.14.95","article-title":"EBF recommendation for stability testing of anti-drug antibodies; lessons learned from anti-vaccine antibody stability studies","volume":"6","author":"Pihl","year":"2014","journal-title":"Bioanalysis"},{"key":"10.1016\/j.jim.2026.114124_bb0120","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s40259-016-0174-5","article-title":"Assessing the immunogenicity of biopharmaceuticals","volume":"30","author":"Pineda","year":"2016","journal-title":"BioDrugs"},{"key":"10.1016\/j.jim.2026.114124_bb0125","series-title":"Connective Tissue and its Heritable Disorders: Molecular, Genetic, and Medical Aspects","author":"Royce","year":"2003"},{"key":"10.1016\/j.jim.2026.114124_bb0130","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1208\/s12248-014-9599-2","article-title":"Assessment and reporting of the clinical immunogenicity of therapeutic proteins and peptides-harmonized terminology and tactical recommendations","volume":"16","author":"Shankar","year":"2014","journal-title":"AAPS J."},{"key":"10.1016\/j.jim.2026.114124_bb0135","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1208\/s12248-025-01030-z","article-title":"Stability of anti-drug antibodies against antibody therapeutics","volume":"27","author":"Sirohi","year":"2025","journal-title":"AAPS J."},{"key":"10.1016\/j.jim.2026.114124_bb0140","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s11882-022-01055-w","article-title":"Human monoclonal IgE antibodies-a major milestone in allergy","volume":"23","author":"Smith","year":"2023","journal-title":"Curr Allergy Asthma Rep"},{"key":"10.1016\/j.jim.2026.114124_bb0145","doi-asserted-by":"crossref","DOI":"10.1186\/1750-1172-8-42","article-title":"Phase I\/II clinical trial of enzyme replacement therapy with idursulfase beta in patients with mucopolysaccharidosis II (Hunter syndrome)","volume":"8","author":"Sohn","year":"2013","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.jim.2026.114124_bb0150","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/3072586","article-title":"Understanding the supersensitive anti-drug antibody assay: unexpected high anti-drug antibody incidence and its clinical relevance","author":"Song","year":"2016","journal-title":"J. Immunol. Res."},{"key":"10.1016\/j.jim.2026.114124_bb0155","author":"U.S. Food and Drug Administration"},{"key":"10.1016\/j.jim.2026.114124_bb0160","author":"U.S. Food and Drug Administration"},{"key":"10.1016\/j.jim.2026.114124_bb0165","doi-asserted-by":"crossref","first-page":"2467","DOI":"10.2147\/DDDT.S139601","article-title":"Development of idursulfase therapy for mucopolysaccharidosis type II (hunter syndrome): the past, the present and the future","volume":"11","author":"Whiteman","year":"2017","journal-title":"Drug Des. Devel. Ther."},{"key":"10.1016\/j.jim.2026.114124_bb0170","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s00431-007-0635-4","article-title":"Mucopolysaccharidosis type II (hunter syndrome): a clinical review and recommendations for treatment in the era of enzyme replacement therapy","volume":"167","author":"Wraith","year":"2008","journal-title":"Eur. J. Pediatr."}],"container-title":["Journal of Immunological Methods"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022175926001006?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022175926001006?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T02:21:42Z","timestamp":1790389302000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022175926001006"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":34,"alternative-id":["S0022175926001006"],"URL":"https:\/\/doi.org\/10.1016\/j.jim.2026.114124","relation":{},"ISSN":["0022-1759"],"issn-type":[{"value":"0022-1759","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development and validation of an ELISA-based assay for detecting anti-idursulfase beta IgE antibodies in human serum using a conjugated IgG-IgE positive control antibody","name":"articletitle","label":"Article Title"},{"value":"Journal of Immunological Methods","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jim.2026.114124","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"114124"}}